NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q3 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $117 | -8.6% | 170,100 | +200.0% | 0.00% | -100.0% |
| Q4 2022 | $128 | -99.9% | 56,700 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $181,000 | -15.8% | 56,700 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $215,000 | +481.1% | 56,700 | +2418.9% | 0.00% | – |
| Q3 2020 | $37,000 | -28.8% | 2,251 | 0.0% | 0.00% | – |
| Q2 2020 | $52,000 | +30.0% | 2,251 | 0.0% | 0.00% | – |
| Q1 2020 | $40,000 | -16.7% | 2,251 | 0.0% | 0.00% | – |
| Q4 2019 | $48,000 | -41.5% | 2,251 | -50.0% | 0.00% | – |
| Q3 2019 | $82,000 | +2.5% | 4,502 | +100.0% | 0.00% | – |
| Q2 2019 | $80,000 | -83.6% | 2,251 | -84.5% | 0.00% | -100.0% |
| Q1 2019 | $488,000 | +23.2% | 14,552 | +20.5% | 0.00% | 0.0% |
| Q4 2018 | $396,000 | -77.7% | 12,074 | -58.6% | 0.00% | -75.0% |
| Q3 2018 | $1,778,000 | +60.6% | 29,175 | +28.6% | 0.01% | +60.0% |
| Q2 2018 | $1,107,000 | -71.6% | 22,689 | -38.2% | 0.01% | -70.6% |
| Q1 2018 | $3,899,000 | +107.3% | 36,700 | +16.5% | 0.02% | +112.5% |
| Q4 2017 | $1,881,000 | +378.6% | 31,500 | +92.1% | 0.01% | +300.0% |
| Q3 2017 | $393,000 | +42.9% | 16,400 | +16.3% | 0.00% | +100.0% |
| Q2 2017 | $275,000 | -36.9% | 14,100 | -24.2% | 0.00% | -50.0% |
| Q1 2017 | $436,000 | +175.9% | 18,600 | +102.2% | 0.00% | +100.0% |
| Q3 2016 | $158,000 | +69.9% | 9,200 | +39.4% | 0.00% | – |
| Q2 2016 | $93,000 | +106.7% | 6,600 | +100.0% | 0.00% | – |
| Q1 2016 | $45,000 | -64.8% | 3,300 | -56.6% | 0.00% | -100.0% |
| Q4 2015 | $128,000 | -9.2% | 7,600 | -40.9% | 0.00% | 0.0% |
| Q3 2015 | $141,000 | -11.9% | 12,869 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $160,000 | +13.5% | 12,869 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $141,000 | -45.8% | 12,869 | -23.3% | 0.00% | 0.0% |
| Q4 2014 | $260,000 | +1757.1% | 16,769 | +1189.9% | 0.00% | – |
| Q3 2013 | $14,000 | – | 1,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |